A recent study from the Key Laboratory of Food Safety Research, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China; & Key Laboratory of Food Safety Risk Assessment, Ministry of Health, Beijing, China shows that “Hepatic p38α regulates gluconeogenesis by suppressing AMPK.” This study was published in the 13 Jan 2015 issue of “Journal of Hepatolgy“[the no. 1 research journal in Hepatalogy with an impact factor of 10.4) by Prof Hao Ying, Yanyan Jing, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Hyperglycemia & T2DM: Panax ginseng increases the expression of AMPK (5′ adenosine monophosphate-
Given that (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; (3) DM is often associated with a number of other diseases such as hypertension, myocardial infarction, cardiac hypertrophy etc; and (4) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find a side-effect-free natural product-based drug to treat Hyperglycemia & DM.
This study suggests, for the first time, that Panax ginseng, by increasing the expression of its target gene, it may increase the expression of AMPK. Thereby, it may lower hepatic glucose production and plasma glucose levels. Thus, pharmacological formulations encompassing “Panax ginseng” may be used to treat DM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Hyperglycemia & T2DM: Panax ginseng increases the expression of AMPK(5′ adenosine monophosphate-
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation